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ABSTRACT
Tumorigenesis is a multi-step process that reflects intimate reciprocal interactions between epithelia and underlying stroma. However, tumor-initiating mechanisms coordinating transformation of both epithelial and stromal components are not defined.
In humans and mice, initiation of colorectal cancer is universally associated with loss of guanylin and uroguanylin, the endogenous ligands for the tumor suppressor guanylyl cyclase C (GUCY2C), disrupting a network of homeostatic mechanisms along the cryptsurface axis. Here, we reveal that silencing GUCY2C in human colon cancer cells increases Akt-dependent TGF-ɴ secretion, activating fibroblasts through TGF-ɴ type I receptors and Smad3 phosphorylation. In turn, activating TGF-ɴ signaling induces fibroblasts to secrete hepatocyte growth factor (HGF), reciprocally driving colon cancer cell proliferation through cMET-dependent signaling. Elimination of GUCY2C signaling in mice (Gucy2c -/-) produces intestinal desmoplasia, with increased reactive myofibroblasts, which is suppressed by anti-TGF-ɴ antibodies or genetic silencing of Akt.
Thus, GUCY2C coordinates intestinal epithelial-mesenchymal homeostasis through reciprocal paracrine circuits mediated by TGF-ɴ and HGF. In that context, GUCY2C
signaling constitutes a direct link between the initiation of colorectal cancer and the induction of its associated desmoplastic stromal niche. The recent regulatory approval of oral GUCY2C ligands to treat chronic gastrointestinal disorders underscores the potential therapeutic opportunity for oral GUCY2C hormone replacement to prevent remodeling of the microenvironment essential for colorectal tumorigenesis. 
INTRODUCTION
Tumorigenesis reflects an intimate collaboration between cancer cells and the supporting microenvironmental stroma (1) (2) (3) . Genetic changes underlying malignant transformation corrupt circuits regulating epithelial-mesenchymal cross-talk that are essential for normal tissue organization, homeostasis, and regeneration (4) . This reprogramming drives the co-evolution of epithelial cells and their supporting microenvironment, producing reactive stroma that allows tumor cells to acquire the hallmarks of cancer (2, 5, 6) .
The dynamic changes in cancer-associated stroma resemble the desmoplastic reaction of wound-healing, characterized by extracellular mesenchymal remodeling with increased matrix deposition and matrix metalloproteinase (MMP) activity (4) . Tumorassociated desmoplasia is supported primarily by the transformation of quiescent host fibroblasts into myofibroblasts (1, 2, 7, 8) . While normal stroma contains few fibroblasts, there is an increase in activated myofibroblasts within the reactive stroma surrounding tumors (8) . Induction of the myofibroblastic phenotype in quiescent fibroblasts is supported by the secretion of TGF-ɴ by cancer cells (1, 3, 9) . Reciprocally, myofibroblasts play an essential role in solid tumors by producing paracrine and juxtacrine factors, including HGF, that drive normal epithelial cells toward acquiring the malignant phenotype (1, 5, 6, (10) (11) (12) (13) (14) .
Paracrine cross-talk between epithelia and mesenchyme is essential to cancer progression and metastasis (15) , but the precise signaling mechanisms linking tumor- initiating events to desmoplastic induction remain incompletely defined. For example the cell type coordinating epithelial and mesenchymal reprogramming at the initiation of transformation remains unknown (2, 8, 16) . Thus, dissecting the individual stromal and epithelial contributions would define the paracrine signaling loops initiating and supporting carcinogenesis and provide new targets for tumor prevention and therapy.
Guanylyl cyclase C (GUCY2C) is the intestinal isoform from the family of guanylyl cyclase transmembrane receptor enzymes that signal by producing cGMP (17) . GUCY2C was first identified as the intestinal epithelial receptor regulating fluid and electrolyte transport in the secretory diarrhea induced by bacterial enterotoxins (ST) (17) . Discovery of the endogenous paracrine hormones uroguanylin, in the small intestine, and guanylin, in the colorectum (18) , revealed a role for GUCY2C in epithelial cell dynamics and the homeostatic balance of proliferation, metabolism, and differentiation that organizes the crypt-surface axis in the intestine (19) (20) (21) (22) (23) .
Notably, guanylin and uroguanylin are the most commonly lost gene products in intestinal tumorigenesis in animals and humans, and their expression is universally silenced at the earliest stages of transformation (24-27). Further, eliminating GUCY2C amplifies the tumorigenesis induced by carcinogens or gene mutations in mice (20, 21) .
Indeed, silencing GUCY2C activates the AKT-mTOR signaling axis, which imparts cellautonomous characteristics of transformation to intestinal epithelial cells, encompassing accelerated proliferation, reprogramming of metabolism from oxidative phosphorylation to aerobic glycolysis, and impaired DNA damage repair (19) (20) (21) (22) (23) Moreover, oral administration of GUCY2C hormone attenuates the colorectal tumorigenesis induced by APC mutations in mice (25). GUCY2C has emerged as a novel intestinal tumor suppressor whose silencing through hormone loss universally contributes to the initiation and progression of colorectal cancer.
In the heart, the natriuretic peptide receptor guanylyl cyclase A isoform (NPR1) is expressed in cardiomyocytes and establishes a homeostatic balance with the mesenchymal compartment (28, 29). Silencing cardiomyocyte NPR1 and cGMP signaling produces cardiac hypertrophy and elevated interstitial fibrosis (28, 29). In fact, increases in growth and fibrosis are disproportionate to and perhaps even independent of increases in blood pressure or volume, suggesting that NPR1 acts through local, paracrine pathways to suppress hypertrophy and desmoplasia (28, 29). The paracrine mechanisms mediating this cardiomyocyte-mesenchymal cross-talk remain incompletely characterized. However, based on this role of NPR1 and cGMP signaling in the heart, the present study explored whether the tumor suppressor GUCY2C and cGMP had homologous functions in the intestine, namely the maintenance of epithelialmesenchymal homeostasis whose corruption contributes to tumor-associated desmoplasia.
MATERIALS AND METHODS
Animal models
Gucy2c
-/-wild type littermate mice on the C57BL/6 background (generation 14) were bred, maintained, genotyped, and functionally characterized in accordance with the 
Akt activation and inhibition in cancer cells
T84 were infected with adenovirus-expressing siAKT1 and GFP control for inhibition experiments, or adenovirus-expressing wtAKT1 and myrAKT1 for activation experiments, at 50% confluence using MOI's of 100 at 48 h before GUCY2C activation during starvation (21) . Then, cells were washed and incubated in complete media with 1 ʅM ST or PBS (control) for 48 h. The conditioned media was transferred to fibroblasts after dilution as described above.
HGF production by fibroblasts and cMET activation
Media conditioned by T84 cells with and without activation of GUCY2C signaling by 1 μm ST or PBS (control) for 48 h were used to induce fibroblast activation of CCD-18Co cells following incubation for 24 h. Then, fibroblast-conditioned media were transferred to HCT116 human colon cancer cells, which do not express GUCY2C and possess inactivating mutations in the TGF-ɴ receptor (21, 31) , and proliferation was quantified Figure 1 , the interstitial thickness was calculated as: area of the blue stain divided by the length of the underlying muscle layer, quantified in Image J. In Figure 6 , the interstitial thickness displays the shortest distance between the bottom of the crypt and the muscle layer. In both cases, pixels were converted back to 
Hydroxyproline assay
Tissue was freeze-dried, homogenized, and hydrolyzed in 0.5 mL of 5 M HCl for 16 h at 116 o C. Samples were dried, dissolved in distilled water, and hydroxyproline quantified using a colorimetric demethylmethylene blue assay (Sigma-Aldrich, MO) (34).
Collagen contractility assay
CCD-18Co cells and Type I Collagen (Sigma-Aldrich, MO) dissolved in acetic acid (0.1%) was used to access functional differences in contractility between quiescent fibroblasts and fibroblasts (35) . After solutions were neutralized with NaOH (1 μM), cells were suspended in the collagen, plated, and cancer cell-conditioned media was added (35) .
Quantitative RT-PCR
Total RNA was subjected to one-step RT-PCR using TaqMan® EZ RT-PCR Core Reagents and specific primer/probes for TaqMan® Gene Expression Assays in an ABI 7000 (Applied Biosystems, CA) (36) . Relative expression was calculated using the 2-ѐѐCT method with GAPDH or ɴ-actin as reference (36) .
Electron microscopy
Intestinal samples were collected, processed, fixed and embedded as previously described (21) . Ninety nm sections were imaged with a JEOL-1010 electron microscope employing 80 kV of acceleration. 
Statistical analyses
Statistical significance was determined by unpaired two-tailed Student's t test. Unless otherwise indicated, results represent means ± SEM from >3 animals or >3 experiments performed in triplicate.
RESULTS
GUCY2C in epithelial cells opposes desmoplasia
The absence of epithelial GUCY2C signaling in Gucy2c knockout mice (Gucy2c -/-) produced submucosal hypertrophy ( Also, absence of epithelial GUCY2C signaling increased submucosal fibroblast content, particularly in the pericryptal sheath ( Fig. 1C1, 1C2 ), an anatomical location driving mesenchymally-directed epithelial cell proliferation (8, 38) . Further, these cells were identified as fibroblasts, reflected by increased transcription ( activating ligand (ST) were collected and used to treat CCD-18Co human fibroblasts. T84 cells express GUCY2C, which mediates canonical downstream cGMP signaling upon ligand binding (20) (21) (22) . In contrast, CCD-18Co cells do not express GUCY2C and are unresponsive to ligands targeting that receptor. As quantified by activated fibroblast numbers ( Fig. 2A), matrix synthesis (Fig. 2B) , and contraction of collagen (Fig. 2C) (1, 7, 8,   35 ), conditioned media from T84 cells without ST treatment produced fibroblast activation, which was markedly reduced by ST.
Epithelial GUCY2C regulates fibroblast activation through TGF-ɴ secretion
TGF-ɴ is an established mediator of fibroblast activation and desmoplasia whose secretion characterizes the entire developmental continuum of solid tumors in animals and humans (1, 2, 7, 8, 11) . GUCY2C activation by ST did not alter transcription of TGF-ɴ, but markedly increased TGF-ɴ retention and decreased TGF-ɴ secretion, by cancer cells (Fig. 3A, B) . In a series of conditioned-media experiments, media conditioned by T84 human colon cancer cells were collected and used to treat CCD-18Co human fibroblasts.
Reducing TGF-ɴ mRNA expression and protein secretion in cancer cells with siRNA ( Fig.3A) mimicked ST-induced GUCY2C signaling and opposed fibroblast activation, including collagen contractility and translation of biomarkers of activation, by conditioned media (Fig. 3C-D) . Inhibiting fibroblast TGF-ɴ type I receptors with TGF-ɴ receptor inhibitor SB-505124 also mimicked ST-induced GUCY2C signaling and opposed fibroblast activation by conditioned media (Fig. 3E) . Further, cancer cell-conditioned media activated fibroblast TGF-ɴ receptor signaling through phosphorylation of the TGF- ɴ signaling target Smad-3, and GUCY2C signaling in cancer cells blocked that effect (Fig.   3F ).
Additionally, a neutralizing antibody to secreted TGF-ɴ reduced both the fibroblast activation (Fig. 4A ) and the Smad-3 phosphorylation (Fig. 4B ) induced by cancer cellconditioned media. The effects of neutralizing antibodies on fibroblast activation and TGF-ɴ signaling were abrogated when TGF-ɴ was re-introduced by adding recombinant purified TGF-ɴ (rTGB-ɴ) (Fig. 4A-B) . To reinforce these in vitro findings, in vivo studies were conducted in which Gucy2c -/-mice were treated with TGF-ɴ neutralizing antibodies.
Antibody administration reversed the submucosal desmoplasia (Fig. 4C ), reducing interstitial thickness (Fig. 4C) , total collagen deposition ( Fig. 4D ), Smad-3 phosphorylation (Fig. 4E) , and fibroblast activation (Fig. 4F ). These data reveal that GUCY2C mediates an efferent mucosal paracrine limb which modulates epithelial TGF-ɴ secretion and fibroblast activation through TGF-ɴ receptors and Smad-3 phosphorylation, and thereby shapes the submucosal microenvironment to oppose the desmoplastic reaction.
GUCY2C regulates epithelial TGF-ɴ secretion and fibroblast activation through Akt
GUCY2C regulates epithelial cell homeostasis and suppresses tumorigenesis through the Akt signaling pathway (21) . Notably, studies have also demonstrated that Akt regulates the secretion of TGF-ɴ in mechanisms remodeling the stroma microenvironment (39) . In vitro, elimination of AKT expression with siRNA (siAkt) mimicked ST-induced GUCY2C
signaling, and replicated the effects of ST on cancer cell secretion of TGF-ɴ (Fig. 5A ) and (Fig. 5B) . Conversely, constitutive activation of AKT by myristoylation (myrAKT) (21) mimicked the absence of GUCY2C signaling, and blocked the reverting effects of ST, leading to the promotion of TGF-ɴ secretion (Fig. 5C) .
Moreover, reducing AKT expression through gene disruption in vivo subdued the stromal remodeling produced by silencing GUCY2C (Fig. 5D) . These observations support a model in which, as in other homeostatic processes like proliferation and metabolism (19) (20) (21) (22) (23) , the regulation of epithelial TGF-ɴ secretion, fibroblast activation, and stromal remodeling by GUCY2C is mediated through epithelial AKT signaling.
GUCY2C reciprocally regulates fibroblast-dependent epithelial cell hyperproliferation
Beyond the contribution of efferent mucosal signals to submucosal fibroblasts, mechanisms by which this microenvironmental re-programming reciprocally contributes to an afferent paracrine loop modulating epithelial hyperproliferation remain incompletely defined (1, 2, 7, 8) . To investigate this afferent loop, we conducted a series of in vitro experiments employing sequentially conditioned media: media conditioned by human colon cancer cells were collected and used to activate human fibroblasts; and the media conditioned by these activated fibroblasts were collected and applied to human colon cancer cells.
In one study, CCD-18Co human fibroblasts were activated by TGF-ɴ at different concentrations, and the conditioned media was collected. Application of this fibroblastconditioned media drove proliferation of human colon cancer cells, as quantified by 3 Hthymidine incorporation, in a TGF-ɴ concentration-dependent manner (Fig. 6A ). 
Similarly, colon cancer cell-conditioned media activated fibroblasts, which, in turn, produced conditioned media that reciprocally drove the proliferation of HCT116 human colon cancer cells, which do not express GUCY2C or TGF-ɴ receptors (Fig. 6B) . However, the ability of fibroblasts to drive epithelial proliferation was eliminated by pre-treating epithelial cell-conditioned media with TGF-ɴ neutralizing antibodies (Fig. 6B) . Further, when treated with media from cancer cells incubated with the GUCY2C ligand ST, fibroblasts failed to drive epithelial proliferation (Fig. 6B) . Exogenous supplementation of fibroblasts with rTGF-ɴ reconstituted the fibroblast-conditioned media's capacity to induce epithelial proliferation, abrogating the effects of TGF-ɴ neutralizing antibody or GUCY2C signaling (Fig. 6B) . These results reveal that GUCY2C signaling regulates the epithelial secretion of TGF-ɴ, which not only activates fibroblasts, but also induces them to release factors that reciprocally feed back to drive epithelial cell proliferation.
Desmoplastic fibroblast activation is associated with expression of the mitogen HGF (Fig.   1D ), a mediator of microenvironmental influences on epithelial cells, including stromal induction of epithelial proliferation (1, 2, 7, 8, 11, 40) . In agreement with previous studies, HGF induced HCT116 human colon cancer cells to proliferate in a concentrationdependent fashion (Fig. 6C) . Further, pretreatment of cancer cells with ST reduced HGF mRNA and protein production from fibroblasts that were activated by TGF-ɴ secreted from colon cancer cells , (Fig. 6D) . In turn, those fibroblast-conditioned media activated cMET, the canonical receptor for HGF (32) , in HCT116 cells. This effect was eliminated by pre-treating fibroblast-conditioned media with HGF neutralizing antibody, an effect 
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reversed by recombinant HGF (rHGF; Fig. 6E ). Moreover, ST-activated GUCY2C signaling in epithelial cells reduced their ability to induce fibroblasts to drive colon cancer cell proliferation ( Fig. 6B and F) . This effect was replicated by adding HGF neutralizing antibodies or an inhibitor of cMET to the fibroblast-conditioned media and blocked by rHGF (Fig. 6F) . These observations suggest a model in which GUCY2C mediates an efferent paracrine circuit regulating the epithelial secretion of TGF-ɴ, and the consequent activation of fibroblasts. In turn, TGF-ɴ ultimately induces a reciprocal afferent paracrine circuit in which the activated stromal fibroblasts produce HGF, which promotes cMET-dependent epithelial cell proliferation (Fig. 7) .
DISCUSSION
Undergoing continuous cycles of regeneration, the intestinal crypt-surface axis is dynamic. GUCY2C signaling organizes the spatiotemporal tissue pattern, maintaining homeostasis along this axis (19) (20) (21) (22) (23) . Specifically, GUCY2C controls epithelial cell proliferation by regulating the expression of critical mediators that slow the cell cycle (19) (20) (21) (22) (23) . Further, GUCY2C and cGMP signaling establish cell fate by promoting the differentiation of epithelial cells in the secretory lineage, which includes Paneth and goblet cells (19) . These effects define the balance between the relative sizes of proliferating and differentiated cell compartments along the crypt-surface axis (19) (20) (21) (22) (23) .
Moreover, GUCY2C is key in matching the appropriate metabolic program to the functional demands along this axis. Namely, low GUCY2C signaling in the crypt favors glycolysis to support rapidly proliferating transit-amplifying cells (21) . Conversely, robust The present study expands the homeostatic role for GUCY2C beyond these cellautonomous functions to coordinating the paracrine cross-talk between the epithelial and mesenchymal compartments that is essential for normal tissue patterning (1, 3, 40) .
Indeed, it suggests a model in which mucosal GUCY2C coordinates bi-directional epithelial-mesenchymal cross-talk in the intestine (Fig. 7) . In this model, GUCY2C signaling in the epithelium opposes an efferent mucosal paracrine loop by suppressing the epithelial secretion of TGF-ɴ, the activation of submucosal fibroblasts, and the desmoplastic reaction. In turn, the suppression of fibroblast activation by GUCY2C-regulated paracrine signaling reduces HGF, silencing an afferent loop that drives epithelial cell proliferation. Notably, this GUCY2C function in the intestinal mucosa recapitulates that of the related guanylyl cyclase isoform NPR1 in cardiomyocytes (28, 29). NPR1 coordinates mesenchymal homeostasis in the heart, and its silencing produces cardiac fibrosis that is independent of increases in blood pressure (28, 29).
Targeted NPR1 knockout (Npr1 -/-) produces local extracellular matrix remodeling in paracrine pathways involving increased TGF-ɴ (28, 29).
The discovery that GUCY2C underlies spatiotemporal patterning along the crypt-surface axis expands its role in the homeostatic maintenance of the intestinal mucosae (19, 22) .
Moreover, it highlights the emergence of GUCY2C as a tumor suppressor universally Silencing GUCY2C establishes a number of cell-autonomous mechanisms underlying epithelial cell tumorigenesis (6) . Thus, the cell cycle is accelerated, expanding the proliferating crypt compartment (19) (20) (21) (22) (23) . Further, metabolic programming is shifted from mitochondrial oxidative phosphorylation to aerobic glycolysis characterizing the Warburg metabolic phenotype (21) . Moreover, genomic instability is accelerated by over-production of reactive oxygen species and exacerbated by a decrease in the ability to repair DNA damage (20, 21) . Indeed, eliminating GUCY2C signaling induces Apc loss of heterozygosity in Apc min mice and the acquisition of mutations in ɴ-catenin in mice treated with the carcinogen AOM, encompassing the genomic changes underlying nearly all sporadic intestinal tumorigenesis in humans (20) . The present study expands the role of GUCY2C as a tumor suppressor whose silencing not only corrupts cellautonomous pathways regulating epithelial transformation, but also epithelialmesenchymal paracrine circuits underlying fibroblast activation and desmoplasia, a process which universally contributes to tumorigenesis in most tissues (2, 5, 6 ). Beyond this question of compartmental hierarchy, the relationship between canonical networks whose corruption initiates neoplasia, and reciprocal paracrine signaling axes organizing epithelial-mesenchymal cross-talk producing desmoplasia, remains undefined.
For example, nearly all sporadic colorectal tumors harbor mutations in the WNT signaling pathway, primarily in APC (about 80%) or ɴ-catenin (about 15%), which drive cell-autonomous changes in epithelia (41, 43, 47) . However, the precise linkages between corrupted WNT signaling pathways underlying tumorigenesis and mechanisms coordinating desmoplasia characterizing colorectal cancer remain unknown. The present study offers a mechanistic explanation for coordination of epithelial transformation and the development of the desmoplastic reaction in colorectal cancer.
Indeed, silencing GUCY2C in epithelial cells appears to be one of the earliest universal changes in colorectal carcinogenesis (24-27), with the ability to promote genomic instability and mutations in WNT signaling pathway intermediates (20) . In this model, silencing the GUCY2C tumor suppressor early in transformation corrupts cellautonomous functions that are essential for transformation, including proliferation, metabolism, and DNA damage and repair (19) (20) (21) (22) (23) . Moreover, the present study reveals that silencing GUCY2C simultaneously initiates AKT-dependent paracrine signaling through increased epithelial cell TGF-ɴ secretion, activating fibroblasts that reshape the mesenchymal matrix compartment, producing the desmoplastic reaction promoting colorectal tumor invasion and progression. 
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There continues to be intense interest in elucidating the precise compartmental contributions, and their sequence, underlying epithelial-mesenchymal cross-talk contributing to neoplasia (16) . Deconvoluting this spatiotemporal signaling sequence could provide therapeutic targets that disrupt the mutually reinforcing intercompartmental cycle essential for tumor initiation, progression, invasion, and metastasis (1, 2, 4, 5, 8, 16 ). This challenge is underscored by the incompletely understood role of TGF-ɴ in tumorigenesis, sometimes referred to as the "TGF-ɴ Paradox" (11, 48, 49) . On the one hand, TGF-ɴ has potent anti-proliferative properties in epithelial cells, and silencing tumor cell TGF-ɴ receptors by mutation is a key genomic event mediating progression of colorectal tumorigenesis (41) . On the other hand, TGF-ɴ is one of the most potent drivers of quiescent fibroblast transformation to the fibroblast phenotype, although the precise compartment producing this cytokine driving desmoplasia remains uncertain (1, 2, 5, 8) . Moreover, the activity of TGF-ɴ on the stroma can promote tumor initiation, progression, and metastasis (50) . Similarly, although HGF, which drives epithelial proliferation through cMET, is produced by fibroblasts in desmoplasia, the events inducing that production remain uncharacterized in most tumors (1, 2, 5, 8) . In that context, the present study provides insight into the spatiotemporal sequence of signaling interactions coordinating events that drive tumor In some experiments, cMET was inhibited by cMet Kinase Inhibitor III (500 nM; cMET Inhibitor). Processed media were then incubated with HCT116 human colon cancer cells, followed by quantification of proliferation by 3 H-thymidine incorporation. Data in 6A, 6B, 6C, and 6F are representative of >3 experiments. Data in 6D and 6E represent means of n3 experiments ± SEM. p<0.05; **, p<0.01, or n.s. p>0.05. 
